Novocure Ltd logo

Novocure Ltd

NVCR | NASDAQ
Chart Builder DCF Calculator
$16.53
-$0.16 (-0.96%)
At close: Sep 21, 2026, 4:00 PM ET
$17.38
+$0.85 (+5.14%)
Pre-market: Sep 22, 2026, 9:09 AM ET

Company Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

Key Executives

Name Position
Frank Leonard Chief Executive Officer & Director
Christoph Brackmann Chief Financial Officer
Mukund Paravasthu Chief Operating Officer
Adam Daney Head of Investor Relations
Barak Ben Arye General Counsel
Michael Puri Chief Human Resources Officer
Uri Weinberg Chief Innovation Officer & Chief Medical Officer
William F. Doyle Executive Chairman

Latest SEC Filings

Date Type Title
Sep 01, 2026 8-K Current Report
Jul 23, 2026 8-K Current Report
Jul 23, 2026 10-Q Quarterly Report
Jul 01, 2026 4 Filing
Jul 01, 2026 4 Filing
Jul 01, 2026 4 Filing
Jul 01, 2026 4 Filing
Jun 30, 2026 8-K Current Report
Jun 18, 2026 8-K Current Report
Jun 05, 2026 8-K Current Report
View All SEC Filings
Novocure Ltd
Novocure Ltd logo
Country Switzerland
IPO Date Oct 1, 2015
Industry Medical - Devices
Sector Healthcare
Employees 1,605
CEO Frank Leonard

Contact Details

Neuhofstrasse 21 Baar 6340 Switzerland

Stock Details

Ticker Symbol NVCR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001645113
CUSIP Number G6674U108
ISIN Number JE00BYSS4X48
SIC Code 3841

© 2026 bestshares.com. All rights reserved.